BioAdvance News

Jenrin Discovery’s Non-Brain Penetrant Cb1 Antagonists Show Beneficial Effects in Treating Diabetes and Obesity

By WebmasterOctober 30, 2008November 1st, 2024No Comments

Jenrin Discovery’s Non-Brain Penetrant Cb1 Antagonists Show Beneficial Effects in Treating Diabetes and Obesity
Read more here

Previous PostTorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma
Next PostInfraScan Launches International Sales of a Handheld Brain Hematoma Detector